Abstract
To investigate the efficacy of i.v. IgG treatment in pediatric patients with inflammatory lung disease, a prospective, controlled clinical trial was carried out over a 2-year study period. Patients were enrolled on the basis of severe clinical symptomatology. After 1 year of conventional treatment, the patients received 400 mg/kg per month of an i.v. IgG product containing only trace amounts of IgG3 in addition to their regular treatment throughout the second year. Significant clinical improvement, as documented by duration of hospital stay (first year 27.8 days, second year 4.9 days), use of antibiotics (132.8 versus 30.9 days) and use of steroids (21.4 versus 0.7 days) could be observed. Data obtained on a subgroup of patients with IgG3 deficiency were analysed separately. These results indicate that patients with severe chest disease who have IgG3 deficiency will also benefit from i.v. IgG treatment. The mode of action cannot be attributed to replacement of the respective isotypes, but is probably due to the effect of i.v. IgG in preventing repeated viral infections.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bernatowska E., Madaliński K., Janowicz W., Weremowicz R., Gutkowski P., Wolf H. M., Eibl M. M. Results of a prospective controlled two-dose crossover study with intravenous immunoglobulin and comparison (retrospective) with plasma treatment. Clin Immunol Immunopathol. 1987 May;43(2):153–162. doi: 10.1016/0090-1229(87)90123-1. [DOI] [PubMed] [Google Scholar]
- Björkander J., Bake B., Oxelius V. A., Hanson L. A. Impaired lung function in patients with IgA deficiency and low levels of IgG2 or IgG3. N Engl J Med. 1985 Sep 19;313(12):720–724. doi: 10.1056/NEJM198509193131203. [DOI] [PubMed] [Google Scholar]
- Geller-Bernstein C., Kahane P., Weisglass L., Lahav M. Serum immunoglobulins in children with asthma associated with severe respiratory tract infections. Ann Allergy. 1976 Aug;37(2):126–132. [PubMed] [Google Scholar]
- Hanson L. A., Björkander J., Wadsworth C. Intramuscular and intravenous administration of immunoglobulin to patients with hypogammaglobulinemia. Birth Defects Orig Artic Ser. 1983;19(3):205–207. [PubMed] [Google Scholar]
- Newburger J. W., Takahashi M., Burns J. C., Beiser A. S., Chung K. J., Duffy C. E., Glode M. P., Mason W. H., Reddy V., Sanders S. P. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986 Aug 7;315(6):341–347. doi: 10.1056/NEJM198608073150601. [DOI] [PubMed] [Google Scholar]
- Oxelius V. A. Quantitative and qualitative investigations of serum IgG subclasses in immunodeficiency diseases. Clin Exp Immunol. 1979 Apr;36(1):112–116. [PMC free article] [PubMed] [Google Scholar]
- Page R., Friday G., Stillwagon P., Skoner D., Caliguiri L., Fireman P. Asthma and selective immunoglobulin subclass deficiency: improvement of asthma after immunoglobulin replacement therapy. J Pediatr. 1988 Jan;112(1):127–131. doi: 10.1016/s0022-3476(88)80137-9. [DOI] [PubMed] [Google Scholar]
- Roberton D. M., Björkander J., Henrichsen J., Söderström T., Hanson L. A. Enhanced IgG1 and IgG3 responses to pneumococcal polysaccharides in isolated IgA deficiency. Clin Exp Immunol. 1989 Feb;75(2):201–205. [PMC free article] [PubMed] [Google Scholar]
- Roifman C. M., Lederman H. M., Lavi S., Stein L. D., Levison H., Gelfand E. W. Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease. Am J Med. 1985 Aug;79(2):171–174. doi: 10.1016/0002-9343(85)90006-3. [DOI] [PubMed] [Google Scholar]
- Roifman C. M., Levison H., Gelfand E. W. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet. 1987 May 9;1(8541):1075–1077. doi: 10.1016/s0140-6736(87)90494-6. [DOI] [PubMed] [Google Scholar]